BackHemab Therapeutics Holdings Common Stock Overview

Hemab Therapeutics Holdings Common Stock Accounts Payable

Track Hemab Therapeutics Holdings Common Stock's accounts payable ($5.7M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$5.68M

Peer average / median

Loading

Hemab Therapeutics Holdings Common Stock Accounts Payable History

Loading

Hemab Therapeutics Holdings Common Stock vs. peers: Accounts Payable Comparison

Loading

Hemab Therapeutics Holdings Common Stock Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Hemab Therapeutics Holdings Common Stock (COAG) FAQ

The latest accounts payable for COAG is $5.7M as of March 2026. Investors often review this figure alongside Hemab Therapeutics Holdings Common Stock's historical trend and sector peers before judging valuation or financial health.

A accounts payable figure of $5.7M for COAG is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting COAG's accounts payable ($5.7M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Hemab Therapeutics Holdings Common Stock's accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.